For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) ...
Three-month romosozumab followed by denosumab is noninferior to a 12-month course for total hip BMD gains in postmenopausal osteoporosis.
Findings from a phase 3 trial showed denosumab-dssb had comparable efficacy, safety, immunogenicity, PK and PD to Prolia in patients with postmenopausal osteoporosis. Ospomyv is approved to treat ...
Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, received FDA approval for osteoporosis and bone loss treatment. Clinical studies confirmed equivalent efficacy, safety, and pharmacokinetics between ...
Some of the most commonly used medications for osteoporosis can lead to osteonecrosis of the jaw (ONJ), a rare but serious side effect. "Inflammation and infection [in the mouth] plus a potent ...
Many Type 1 diabetes clinical trials require that those enrolling be within six months of their Type 1 diabetes diagnosis. This can limit the number of eligible individuals who can participate in the ...
The US Food and Drug Administration (FDA) has approved denosumab-bnht (Conexxence/Bomyntra), manufactured by Fresenius Kabi, for all indications of the reference ...
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results